Investor Relations

Focused on enhancing shareholder value through creating and delivering meaningful advancements in early intervention orthopedic care.
Stock quote is delayed by 15 minutes
NASDAQANIK
Woman throwing punch at punching bag.

Investor Relations

Focused on enhancing shareholder value through creating and delivering meaningful advancements in early intervention orthopedic care.
Stock quote is delayed by 15 minutes
NASDAQANIK
Financial and Operational Metrics

(As of December 31, 2022)

  • $156M

    FY’22 Revenue

    6% YtY Growth

  • 11%

    Revenue CAGR

    FY’19 – FY’22

  • #1

    U.S. Market Share

    OA Pain Management

  • $86M

    Cash balance
    with no debt

Recent News
Feb 27, 2024

BEDFORD, Mass., February 27, 2024 -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue...

Feb 13, 2024

Announcing the limited market release of X-TwistÔ Fixation System with biocomposite suture anchor for rotator cuff and other soft tissue repair at AAOS Focusing on its full Regenerative, Sports...

Nov 28, 2023

Integrity marks Anika’s entrance into the fast-growing $150 million+2 U.S. rotator cuff augmentation market and expansion of its proprietary hyaluronic acid (HA) regenerative portfolio BEDFORD,...

All Press Releases

Current Investor Presentation
Investor Contacts

Primary IR Contact

  • Mark Namaroff

    Vice President, Investor Relations, ESG, and Corporate Communications

    Anika Therapeutics, Inc.

    Phone: (781) 457-9287

    Email: investorrelations@anika.com

  • Transfer Agent

    Equiniti Trust Company LLC

    6201 15th Avenue

    Brooklyn NY 11219

    Phone: (800) 967-5449

Want Alerts? Sign up for alerts and never miss an Investor update!

Subscribe

To Top